Linagliptin Viatris (Linagliptin)

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition prevents the breakdown of the incretin hormones GLP‑1 and GIP, leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner, which together lower blood glucose levels.

The dose of Linagliptin Viatris is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. The prescriber will select the appropriate strength and dosing schedule according to current treatment guidelines.

Safety of linagliptin during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Linagliptin Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors, but it is distinguished by its primarily non‑renal elimination, which may reduce the need for dose adjustment in patients with renal impairment. Efficacy and safety profiles are broadly comparable, though individual tolerability can vary.

Linagliptin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Linagliptin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber and not alter the schedule without medical advice.

The most serious risks associated with linagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash with swelling, or signs of liver dysfunction such as jaundice.

Linagliptin should not be used by individuals with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, and it is generally avoided in pregnancy or breastfeeding unless clearly justified by a physician.